Scholarly Index
Geoffrey R. Oxnard
Eli Lilly (United States); 27,158 total citations; 445 total publications; best world rank #30
Eli Lilly (United States)
27,158Total citations
445Total publications
76H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Lung Cancer Treatments and Mutations | Lifetime | 131 | US 73 | 99.62 |
| Cancer Genomics and Diagnostics | Lifetime | 219 | US 139 | 99.53 |
| Lung Cancer Research Studies | Lifetime | 183 | US 93 | 99.22 |
| Colorectal Cancer Treatments and Studies | Lifetime | 332 | US 158 | 98.95 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 541 | US 250 | 98.57 |
| Cancer therapeutics and mechanisms | Lifetime | 430 | US 232 | 97.73 |
| Genetic factors in colorectal cancer | Lifetime | 736 | US 319 | 97.57 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 595 | US 325 | 95.69 |
| Cancer Genomics and Diagnostics | 2021-2025 | 30 | US 16 | 99.67 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 93 | US 38 | 99.42 |
| Genetic factors in colorectal cancer | 2021-2025 | 147 | US 67 | 96.41 |
| Lung Cancer Research Studies | 2021-2025 | 308 | US 101 | 96.26 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 453 | US 147 | 94.52 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 608 | US 213 | 67.31 |